Shweta Nayak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shweta Nayak has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Anthony N. Wakim
Univ Pittsburgh, Med Ctr, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Pittsburgh, PA 15213 USA
1 shared publicationJoseph S. Sanfilippo
Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA
1 shared publication- Nancy E. Davidson
University of Pittsburgh Cancer Institute, Pittsburgh, PA
1 shared publication - Rachel C. Jankowitz
Magee-Womens Hospital of University of Pittsburgh Medical Center, 300 Halket St, Pittsburgh, PA, 15213, USA
1 shared publication Selma Feldman Witchel
Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh Medical Center, Pittsburgh, PA
1 shared publication- Steffi Oesterreich
University of Pittsburgh
1 shared publication
Latest Publications
- 1 December 2014
- Published by Elsevier in Journal of Pediatric and Adolescent Gynecology
- Vol. 27 (6) , e127-e129
Vaginal Foreign Body: A Delayed Diagnosis
- 1 December 2014
- Published by Elsevier in Journal of Pediatric and Adolescent Gynecology
- Vol. 27 (6) , e127-e129
Vaginal Foreign Body: A Delayed Diagnosis
- Open Access
- 1 November 2011
- Published by Springer Nature in Breast Cancer Research
- Vol. 13 (6) , 225
Epigenetics in breast cancer: what's new?
Epigenetic changes are critical for development and progression of cancers, including breast cancer. Significant progress has been made in the basic understanding of how various epigenetic changes such as DNA methylation, histone modification, miRNA expression, and higher order chromatin structure affect gene expression. The present review will focus on methylation and demethylation of histones. While the acetylation of histones has been at the forefront of well-characterized post-translational modifications of histones, including the development of inhibitors targeting de-acetylating enzymes, the past few years have witnessed a dramatic increase in knowledge regarding the role of histone methylation/demethylation. This is an exciting and rapidly evolving area of research, with much promise for potential clinical intervention in several cancers including breast cancer. We also summarize efforts to identity DNA methylation signatures that could be prognostic and/or predictive markers in breast cancer, focusing on recent studies using genome-wide approaches. Finally, we briefly review the efforts made by both the National Institutes of Health Epigenome Project and The Cancer Genome Atlas, especially highlighting the study of breast cancer epigenetics, exciting technological advances, potential roadblocks, and future directions.
- 1 November 2011
- Published by Springer Nature in Breast Cancer Research
- Vol. 13 (6) , 225
Open AccessEpigenetics in breast cancer: what's new?
Epigenetic changes are critical for development and progression of cancers, including breast cancer. Significant progress has been made in the basic understanding of how various epigenetic changes such as DNA methylation, histone modification, miRNA expression, and higher order chromatin structure affect gene expression. The present review will focus on methylation and demethylation of histones. While the acetylation of histones has been at the forefront of well-characterized post-translational modifications of histones, including the development of inhibitors targeting de-acetylating enzymes, the past few years have witnessed a dramatic increase in knowledge regarding the role of histone methylation/demethylation. This is an exciting and rapidly evolving area of research, with much promise for potential clinical intervention in several cancers including breast cancer. We also summarize efforts to identity DNA methylation signatures that could be prognostic and/or predictive markers in breast cancer, focusing on recent studies using genome-wide approaches. Finally, we briefly review the efforts made by both the National Institutes of Health Epigenome Project and The Cancer Genome Atlas, especially highlighting the study of breast cancer epigenetics, exciting technological advances, potential roadblocks, and future directions.
- 1 July 2011
- Published by Elsevier in Fertility and Sterility
- Vol. 96 (1) , e51-e54
Random-start gonadotropin-releasing hormone (GnRH) antagonist–treated cycles with GnRH agonist trigger for fertility preservation
- 1 July 2011
- Published by Elsevier in Fertility and Sterility
- Vol. 96 (1) , e51-e54
Random-start gonadotropin-releasing hormone (GnRH) antagonist–treated cycles with GnRH agonist trigger for fertility preservation